BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for 2009. For the three months ended December 31, 2009, Enzon reported a net loss of $0.2 million or breakeven per diluted share, as compared to a net loss of $0.5 million or $0.01 per diluted share for the fourth quarter of 2008. For the full year ended December 31, 2009, Enzon reported a net income of $1.1 million or $0.02 per diluted share, compared to a net loss of $2.7 million or $0.06 per diluted share for the full year ended December 31, 2008. The 2009 financial results were favorably impacted by the continued improvement in capital structure and improved gross margins associated with the consolidation of the manufacturing facilities. In 2008, the financial results were impacted by costs associated with the evaluation of strategic alternatives.
